Hosam Abdelmonaim Elbaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hosam Abdelmonaim Elbaz has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Yon Rojanasakul
Department of Pharmaceutical Sciences, West Virginia University, Morgantown, USA
4 shared publications - Cerasela Zoica Dinu
Department of Chemical and Biomedical Engineering, West Virginia University, Morgantown, WV 26506, USA
3 shared publications - Maik Hüttemann
Center for Molecular Medicine and Genetics Wayne State University Detroit Michigan USA
3 shared publications - George Augustine O'DOherty
Department of Chemistry, Northeastern University, Boston, MA 02115, USA
2 shared publications Icksoo Lee
College of Medicine, Dankook University, Cheonan-si, Chungcheongnam-do 330-714, Republic of Korea
2 shared publications- Steven P. Zielske
Department of Radiation Oncology and
2 shared publications
Latest Publications
- 2 October 2019
- Published by West Virginia University Libraries
Characterization of the pharmacological effects of digitoxin on lung epithelial cells
Lung diseases (excluding cancer) account for 9% of all disease related mortalities while lung cancer accounts for 30% of cancer related mortalities. Therapeutic maneuvers, as surgery are usually unfeasible given the extreme vitality of the lung. Developing novel therapeutic alternatives for lung cancer requires a thorough understanding on the lung epithelial cell behavior following exposure to drugs. The goal of this dissertation was to examine how molecular and cellular characteristics, such as morphology and cell viability, of lung cancer cells will be altered upon exposure to digitoxin, a cardiac glycosides (CGs) and a digitoxin synthetic analog. CGs are a large family of chemical compounds found in several plants and animal species and have been applied for treating congestive heart failure, cardiac arrhythmias, and atrial fibrillation. The study was conducted on non-small cell lung cancer (NSCLC) cells using several techniques such as different cell proliferation assays, fluorescence microscopy, flow cytometry, western blotting, and confocal microscopy.
- 2 October 2019
- Published by West Virginia University Libraries
Characterization of the pharmacological effects of digitoxin on lung epithelial cells
Lung diseases (excluding cancer) account for 9% of all disease related mortalities while lung cancer accounts for 30% of cancer related mortalities. Therapeutic maneuvers, as surgery are usually unfeasible given the extreme vitality of the lung. Developing novel therapeutic alternatives for lung cancer requires a thorough understanding on the lung epithelial cell behavior following exposure to drugs. The goal of this dissertation was to examine how molecular and cellular characteristics, such as morphology and cell viability, of lung cancer cells will be altered upon exposure to digitoxin, a cardiac glycosides (CGs) and a digitoxin synthetic analog. CGs are a large family of chemical compounds found in several plants and animal species and have been applied for treating congestive heart failure, cardiac arrhythmias, and atrial fibrillation. The study was conducted on non-small cell lung cancer (NSCLC) cells using several techniques such as different cell proliferation assays, fluorescence microscopy, flow cytometry, western blotting, and confocal microscopy.
- 1 April 2016
- Published by Elsevier in Environment International
- Vol. 89-90, 174-178
The association of urinary polycyclic aromatic hydrocarbon biomarkers and cardiovascular disease in the US population
- 1 April 2016
- Published by Elsevier in Environment International
- Vol. 89-90, 174-178
The association of urinary polycyclic aromatic hydrocarbon biomarkers and cardiovascular disease in the US population
- Open Access
- 1 January 2015
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2015, 1-13
Molecular Mechanisms and Therapeutic Effects of (−)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, and Neurodegeneration
With recent insight into the mechanisms involved in diseases, such as cardiovascular disease, cancer, stroke, neurodegenerative diseases, and diabetes, more efficient modes of treatment are now being assessed. Traditional medicine including the use of natural products is widely practiced around the world, assuming that certain natural products contain the healing properties that may in fact have a preventative role in many of the diseases plaguing the human population. This paper reviews the biological effects of a group of natural compounds called polyphenols, including apigenin, epigallocatechin gallate, genistein, and (−)-epicatechin, with a focus on the latter. (−)-Epicatechin has several unique features responsible for a variety of its effects. One of these is its ability to interact with and neutralize reactive oxygen species (ROS) in the cell. (−)-Epicatechin also modulates cell signaling including the MAP kinase pathway, which is involved in cell proliferation. Mutations in this pathway are often associated with malignancies, and the use of (−)-epicatechin holds promise as a preventative agent and as an adjunct for chemotherapy and radiation therapy to improve outcome. This paper discusses the potential of some phenolic compounds to maintain, protect, and possibly reinstate health.
- 1 January 2015
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2015, 1-13
Open AccessMolecular Mechanisms and Therapeutic Effects of (−)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, and Neurodegeneration
With recent insight into the mechanisms involved in diseases, such as cardiovascular disease, cancer, stroke, neurodegenerative diseases, and diabetes, more efficient modes of treatment are now being assessed. Traditional medicine including the use of natural products is widely practiced around the world, assuming that certain natural products contain the healing properties that may in fact have a preventative role in many of the diseases plaguing the human population. This paper reviews the biological effects of a group of natural compounds called polyphenols, including apigenin, epigallocatechin gallate, genistein, and (−)-epicatechin, with a focus on the latter. (−)-Epicatechin has several unique features responsible for a variety of its effects. One of these is its ability to interact with and neutralize reactive oxygen species (ROS) in the cell. (−)-Epicatechin also modulates cell signaling including the MAP kinase pathway, which is involved in cell proliferation. Mutations in this pathway are often associated with malignancies, and the use of (−)-epicatechin holds promise as a preventative agent and as an adjunct for chemotherapy and radiation therapy to improve outcome. This paper discusses the potential of some phenolic compounds to maintain, protect, and possibly reinstate health.
- 1 September 2014
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 59, 192-199
Real-time analysis of the effects of toxic, therapeutic and sub-therapeutic concentrations of digitoxin on lung cancer cells
- 1 September 2014
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 59, 192-199
Real-time analysis of the effects of toxic, therapeutic and sub-therapeutic concentrations of digitoxin on lung cancer cells
- Open Access
- 1 July 2014
- Published by Radiation Research Society in Radiation Research
- Vol. 182 (1) , 50-59
Radiosensitization of Pancreatic Cancer Cells by Metformin through the AMPK Pathway
Pancreatic cancer is relatively radioresistant, however, radiotherapy has been shown to provide efficacy in the treatment of local disease. To increase the effectiveness of radiotherapy in pancreatic cancer, radiosensitizing drugs are under development. In this study, we investigated the radiosensitizing activity of the anti-diabetic drug metformin on pancreatic cancer cells in vitro. We demonstrated that metformin radiosensitized MiaPaCa-2 and Panc1 cells with radiation enhancement ratios (ER) ranging from 1.33–1.45 with metformin concentrations of 30–100 μM, and in addition, we showed that metformin sensitized cells to gemcitabine alone or in combination with radiation treatment. In addition, we found that pancreatic cancer stem cell-like cells showed enhanced radiosensitization in a tumorsphere assay with a REF of 1.66. At these radiosensitizing doses, metformin alone had low toxicity (as shown by >75% clonogenic survival) and did not affect cell cycle. The combination of metformin and radiation yielded greater numbers of γ-H2AX foci after 1 h compared to radiation alone, suggesting increased DNA damage signaling. Examination of the AMPK pathway showed that pharmacological inhibition of AMPK signaling or RNAi of AMPKα1 reversed metformin-mediated radiosensitization. These studies show that metformin radiosensitization of pancreatic cancer cells at micromolar concentration acts through AMPK and may affect DNA damage signaling. The data indicate that metformin may increase the efficacy of radiation therapy for pancreatic cancer.
- 1 July 2014
- Published by Radiation Research Society in Radiation Research
- Vol. 182 (1) , 50-59
Open AccessRadiosensitization of Pancreatic Cancer Cells by Metformin through the AMPK Pathway
Pancreatic cancer is relatively radioresistant, however, radiotherapy has been shown to provide efficacy in the treatment of local disease. To increase the effectiveness of radiotherapy in pancreatic cancer, radiosensitizing drugs are under development. In this study, we investigated the radiosensitizing activity of the anti-diabetic drug metformin on pancreatic cancer cells in vitro. We demonstrated that metformin radiosensitized MiaPaCa-2 and Panc1 cells with radiation enhancement ratios (ER) ranging from 1.33–1.45 with metformin concentrations of 30–100 μM, and in addition, we showed that metformin sensitized cells to gemcitabine alone or in combination with radiation treatment. In addition, we found that pancreatic cancer stem cell-like cells showed enhanced radiosensitization in a tumorsphere assay with a REF of 1.66. At these radiosensitizing doses, metformin alone had low toxicity (as shown by >75% clonogenic survival) and did not affect cell cycle. The combination of metformin and radiation yielded greater numbers of γ-H2AX foci after 1 h compared to radiation alone, suggesting increased DNA damage signaling. Examination of the AMPK pathway showed that pharmacological inhibition of AMPK signaling or RNAi of AMPKα1 reversed metformin-mediated radiosensitization. These studies show that metformin radiosensitization of pancreatic cancer cells at micromolar concentration acts through AMPK and may affect DNA damage signaling. The data indicate that metformin may increase the efficacy of radiation therapy for pancreatic cancer.
- Open Access
- 6 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e88322
Epicatechin Stimulates Mitochondrial Activity and Selectively Sensitizes Cancer Cells to Radiation
Radiotherapy is the treatment of choice for solid tumors including pancreatic cancer, but the effectiveness of treatment is limited by radiation resistance. Resistance to chemotherapy or radiotherapy is associated with reduced mitochondrial respiration and drugs that stimulate mitochondrial respiration may decrease radiation resistance. The objectives of this study were to evaluate the potential of (-)-epicatechin to stimulate mitochondrial respiration in cancer cells and to selectively sensitize cancer cells to radiation. We investigated the natural compound (-)-epicatechin for effects on mitochondrial respiration and radiation resistance of pancreatic and glioblastoma cancer cells using a Clark type oxygen electrode, clonogenic survival assays, and Western blot analyses. (-)-Epicatechin stimulated mitochondrial respiration and oxygen consumption in Panc-1 cells. Human normal fibroblasts were not affected. (-)-Epicatechin sensitized Panc-1, U87, and MIA PaCa-2 cells with an average radiation enhancement factor (REF) of 1.7, 1.5, and 1.2, respectively. (-)-Epicatechin did not sensitize normal fibroblast cells to ionizing radiation with a REF of 0.9, suggesting cancer cell selectivity. (-)-Epicatechin enhanced Chk2 phosphorylation and p21 induction when combined with radiation in cancer, but not normal, cells. Taken together, (-)-epicatechin radiosensitized cancer cells, but not normal cells, and may be a promising candidate for pancreatic cancer treatment when combined with radiation.
- 6 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e88322
Open AccessEpicatechin Stimulates Mitochondrial Activity and Selectively Sensitizes Cancer Cells to Radiation
Radiotherapy is the treatment of choice for solid tumors including pancreatic cancer, but the effectiveness of treatment is limited by radiation resistance. Resistance to chemotherapy or radiotherapy is associated with reduced mitochondrial respiration and drugs that stimulate mitochondrial respiration may decrease radiation resistance. The objectives of this study were to evaluate the potential of (-)-epicatechin to stimulate mitochondrial respiration in cancer cells and to selectively sensitize cancer cells to radiation. We investigated the natural compound (-)-epicatechin for effects on mitochondrial respiration and radiation resistance of pancreatic and glioblastoma cancer cells using a Clark type oxygen electrode, clonogenic survival assays, and Western blot analyses. (-)-Epicatechin stimulated mitochondrial respiration and oxygen consumption in Panc-1 cells. Human normal fibroblasts were not affected. (-)-Epicatechin sensitized Panc-1, U87, and MIA PaCa-2 cells with an average radiation enhancement factor (REF) of 1.7, 1.5, and 1.2, respectively. (-)-Epicatechin did not sensitize normal fibroblast cells to ionizing radiation with a REF of 0.9, suggesting cancer cell selectivity. (-)-Epicatechin enhanced Chk2 phosphorylation and p21 induction when combined with radiation in cancer, but not normal, cells. Taken together, (-)-epicatechin radiosensitized cancer cells, but not normal cells, and may be a promising candidate for pancreatic cancer treatment when combined with radiation.
- 1 October 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 87 (2)
The Mechanism of Metformin-Induced Radiosensitization of Pancreatic Cancer Cells
- 1 October 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 87 (2)
The Mechanism of Metformin-Induced Radiosensitization of Pancreatic Cancer Cells
- Open Access
- 5 April 2012
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 1 (1) , 4
Digitoxin and its analogs as novel cancer therapeutics
A growing body of evidence indicates that digitoxin cardiac glycoside is a promising anticancer agent when used at therapeutic concentrations. Digitoxin has a prolonged half-life and a well-established clinical profile. New scientific avenues have shown that manipulating the chemical structure of the saccharide moiety of digitoxin leads to synthetic analogs with increased cytotoxic activity. However, the anticancer mechanism of digitoxin or synthetic analogs is still subject to study while concerns about digitoxin's cardiotoxicity preclude its clinical application in cancer therapeutics. This review focuses on digitoxin and its analogs, and their cytotoxicity against cancer cells. Moreover, a new perspective on the pharmacological aspects of digitoxin and its analogs is provided to emphasize new research directions for developing potent chemotherapeutic drugs.
- 5 April 2012
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 1 (1) , 4
Open AccessDigitoxin and its analogs as novel cancer therapeutics
A growing body of evidence indicates that digitoxin cardiac glycoside is a promising anticancer agent when used at therapeutic concentrations. Digitoxin has a prolonged half-life and a well-established clinical profile. New scientific avenues have shown that manipulating the chemical structure of the saccharide moiety of digitoxin leads to synthetic analogs with increased cytotoxic activity. However, the anticancer mechanism of digitoxin or synthetic analogs is still subject to study while concerns about digitoxin's cardiotoxicity preclude its clinical application in cancer therapeutics. This review focuses on digitoxin and its analogs, and their cytotoxicity against cancer cells. Moreover, a new perspective on the pharmacological aspects of digitoxin and its analogs is provided to emphasize new research directions for developing potent chemotherapeutic drugs.
- 1 January 2012
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 258 (1) , 51-60
Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells
- 1 January 2012
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 258 (1) , 51-60
Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells
- 12 July 2010
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 1 (7) , 326-330
A Direct Comparison of the Anticancer Activities of Digitoxin MeON-Neoglycosides and O-Glycosides
Digitoxin is a cardiac glycoside currently being investigated for potential use in oncology; however, an investigation of anticancer activity as a function of oligosaccharide chain length has not yet been performed. We generated mono-, di-, and tri-O-digitoxoside derivatives of digitoxin and compared their activities to the corresponding MeON-neoglycosides. Both classes of cardenolide derivatives display comparable oligosaccharide chain length-dependent cytotoxicity toward human cancer cell lines. Further investigation revealed that both classes of compounds induce caspase-9-mediated apoptosis in non-small cell lung cancer cells (NCI-H460). Because O-glycosides and MeON-neoglycosides share a similar mode of action, the convenience of MeON-neoglycosylation could be exploited in future SAR work to rapidly survey large numbers of carbohydrates to prioritize selected O-glycoside candidates for traditional synthesis.
- 12 July 2010
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 1 (7) , 326-330
A Direct Comparison of the Anticancer Activities of Digitoxin MeON-Neoglycosides and O-Glycosides
Digitoxin is a cardiac glycoside currently being investigated for potential use in oncology; however, an investigation of anticancer activity as a function of oligosaccharide chain length has not yet been performed. We generated mono-, di-, and tri-O-digitoxoside derivatives of digitoxin and compared their activities to the corresponding MeON-neoglycosides. Both classes of cardenolide derivatives display comparable oligosaccharide chain length-dependent cytotoxicity toward human cancer cell lines. Further investigation revealed that both classes of compounds induce caspase-9-mediated apoptosis in non-small cell lung cancer cells (NCI-H460). Because O-glycosides and MeON-neoglycosides share a similar mode of action, the convenience of MeON-neoglycosylation could be exploited in future SAR work to rapidly survey large numbers of carbohydrates to prioritize selected O-glycoside candidates for traditional synthesis.